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Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous 
system (CNS) that causes debilitating central neuropathic pain (CNP) in many patients. 
Although mouse models of experimental autoimmune encephalomyelitis (EAE) have 
provided insight on the pathobiology of MS-induced neuropathic pain, concurrent severe 
motor impairments confound quantitative assessment of pain behaviours over the disease 
course. Hence, my PhD research project was designed to establish and characterise an 
optimised mouse model of multiple sclerosis (MS)-induced neuropathic pain using 
behavioural, pharmacological, histological and immunohistochemical methods. I then used 
my optimised EAE-mouse model of MS-neuropathic pain to gain insight on the pathobiology 
of MS-associated neuropathic pain. In the final part of my PhD research project, I 
investigated the analgesic efficacy and mode of action of ‘Treatment-A’ as a novel treatment 
for relief of MS-neuropathic pain.  
 
EAE-rodent models induced by immunisation with myelin oligodendrocyte glycoprotein 
(MOG) are commonly used for research on MS due to their CNS pathological features in 
common with patients with MS. However, a major limitation of most of previously published 
MOG-induced EAE-mouse models is severe motor impairment (e.g. hindlimb paralysis) that 
confounds assessment of behavioural pain endpoints as the disease progresses. To address 
this issue, I systematically optimised the various components of the immunisation protocol 
for induction of mild relapsing-remitting EAE disease in C57BL/6 female mice. My 
optimised immunisation protocol comprised MOG35-55 (200 µg) together with adjuvants 
including Quil A (45 µg) and pertussis toxin (2 x 250 ng). Quil A replaced the traditionally 
used Freund’s Complete adjuvant (FCA), as FCA itself may induces CNS 
neuroinflammation. Apart from inducing a mild relapsing-remitting EAE (RR-EAE) clinical 
disease course in mice, my optimised immunisation protocol also induced temporal 
development of mechanical allodynia in the bilateral hindpaws, but without confounding 
motor deficits. Mechanical allodynia was fully developed in the hindpaws of my RR-EAE 
mice by 28-35 days post-immunisation (p.i.) and it was maintained until study completion 
(55-57 days p.i.). 
 
Next, I pharmacologically characterised my optimised EAE-mouse model of MS-neuropathic 
pain using clinically available analgesic agents. Single bolus doses of amitriptyline, 
gabapentin and morphine (but not vehicle) produced dose-dependent relief of mechanical 
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allodynia in the bilateral hindpaws of EAE-mice; the corresponding ED50s were 1.5, 20 and 1 
mg/kg respectively.  
 
I then used histological and immunohistochemical methods to further characterise my 
optimised EAE-mouse model of MS-neuropathic pain. For this purpose, brain and lumbar 
spinal cord tissues were collected from EAE-, sham- and age-matched (non-immunised)-mice 
at day-39 p.i., a time when mechanical allodynia was fully developed in the bilateral 
hindpaws of EAE-mice. My findings showed significant demyelination, glial cell activation 
and augmented infiltration of CD3+ T-cells into the CNS of RR-EAE mice (but not sham- or 
control-mice), mirroring these hallmark pathological features of MS in humans. Together, 
these findings show that my optimised RR-EAE mouse model has considerable potential for 
investigation of the pathobiological mechanisms underpinning MS-associated neuropathic 
pain. Furthermore, my optimised model is suitable for efficacy profiling of novel analgesics 
for improved relief of MS-induced neuropathic pain.  
 
Upregulation of brain-derived neurotrophic factor (BDNF) and tyrosine kinsase (TrkB) has 
been implicated by others in the pathobiology of peripheral neuropathic pain; however it is 
unknown hitherto in CNP associated with MS. To address this knowledge gap, I next 
investigated the analgesic efficacy of ‘Treatment-A’, and the possibility that it may modulate 
lumbar spinal cord expression levels of BDNF and its receptor TrkB in my optimised EAE-
mouse model of MS-induced neuropathic pain. Briefly, RR-EAE mice were administered 
once-daily subcutaneous (s.c.) doses of ‘Treatment-A’ (3 or 10 mg/kg/day) or vehicle over a 
21 day period (till day-35 p.i.) commencing on the day of clinical disease relapse. 
Importantly, my findings showed that ‘Treatment-A’ dose-dependently and progressively 
alleviated mechanical hypersensitivity in the bilateral hindpaws of my RR-EAE mouse model 
of MS-induced neuropathic pain, whereas vehicle administered similarly, was without effect.  
 
Finally, I showed that the cellular and molecular mechanisms underpinning the pain-relieving 
effects of chronically administered ‘Treatment-A’ at 10 mg/kg/day in RR-EAE mice involves 
a marked reduction in CD3+T-cell infiltration and microglial activation in lumbar spinal cord 
to reduce augmented levels of BDNF-TrkB signalling and pp44/pp42 MAPK (also called 
pERK) that matched the respective levels in the lumbar spinal cord of vehicle-treated sham-
mice. Importantly, the upregulated BDNF-TrkB-ERK signalling in RR-EAE mice treated 
with vehicle was confined to lamina-1 of the dorsal horn in the lumbar spinal cord.   
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In summary, during the course of my PhD, I have successfully established, optimised and 
characterised an RR-EAE mouse model of MS-induced neuropathic pain that is devoid of 
motor deficits. My findings also show that once-daily administration of ‘Treatment-A’ for 21 
days according to an intervention protocol, progressively alleviated mechanical 
hypersensitivity in the bilateral hindpaws of RR-EAE mice in a dose-related manner. 
Treatment-A is worthy of further investigation as a potential novel treatment for relief of MS-
induced neuropathic pain in patients.  
 
